SKP2 and hepatocellular carcinoma: Moreover, our previous studies have shown that TA combined with other CP mutations in the HBV genome enhanced cell cycle progression, cellular growth and colony formation in both HCC cell lines and human primary hepatocytes by influencing SKP2 promoter activity22, 29.